The complication of substituting an antibody in an approved test provides continuity of revenue for AIM outfit
Bioventix (BVXP:AIM) £24.11 Market cap: £127.9 million Opportunities to buy high quality businesses at knock-down prices do not come along every day. We believe specialist antibody maker Bioventix (BVXP:AIM) now falls into this camp. Over the last year Bioventix shares have halved, taking the one-year forward PE (price to earnings) ratio down to 16 times from 29 times. Bioventix is known as more of a growth than an income...